Accepted Manuscript

Title: Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers

Authors: Belinda Lee, Ryan Hutchinson, Hui-Li Wong, Jeanne Tie, Tracy Putoczki, Ben Tran, Peter Gibbs, Michael Christie

PII: S1044-579X(17)30123-2
DOI: https://doi.org/10.1016/j.semcancer.2017.12.009
Reference: YSCBI 1429

To appear in: *Seminars in Cancer Biology*

Received date: 30-6-2017
Revised date: 14-12-2017
Accepted date: 15-12-2017

Please cite this article as: Lee Belinda, Hutchinson Ryan, Wong Hui-Li, Tie Jeanne, Putoczki Tracy, Tran Ben, Gibbs Peter, Christie Michael.Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers.*Seminars in Cancer Biology* https://doi.org/10.1016/j.semcancer.2017.12.009

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers

Belinda Lee[a,b,f,g,§], Ryan Hutchinson[a,e,§], Hui-Li Wong[a,§], Jeanne Tie[a,c,e], Tracy Putoczki[f,g], Ben Tran[a,c], Peter Gibbs[a,b], Michael Christie[a,d,*]

[a]Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

[b]Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.

[c]Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.

[d]Department of Pathology, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia.

[e]Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria 3010, Australia.

[f]Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.

[g]Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

*Corresponding author at: Anatomical Pathology Department, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. Tel. +61393428000. Fax +61393428666. Email: Michael.christie@mh.org

[§]These authors contributed equally to this work.

Abstract

Carcinomas of the oesophagus, stomach, pancreas and liver are common and account for a disproportionately high number of cancer deaths. There is a need for new treatment options for patients with advanced disease. Immunomodulatory treatments including immune checkpoint blockade offer a promising new approach, with efficacy shown in other solid tumour types. However, only a small proportion of patients with carcinomas of the oesophagus, stomach, pancreas and liver have responded to single agent checkpoint inhibitors, and there is a need for markers that are predictive of response to guide treatment of individual patients. Predictive markers may include epidemiological factors such as ethnicity, the genomic status of the tumour, circulating markers, expression of immune checkpoint molecules, and other features

Download English Version:

https://daneshyari.com/en/article/10157004

Download Persian Version:

https://daneshyari.com/article/10157004

Daneshyari.com